ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Transcription factor TFAP2A drives the growth and metastasis and blocks ferroptosis of triple-negative breast cancer by activating PRAME transcription.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Mapping the Subtype-Specific PARP1 ADP-Ribosylated Proteome in Breast Cancer Cells.Molecular cancer research : MCR · 2026Article
- Prognostic value of PRAME gene promoter methylation and expression in hepatocellular carcinoma.Clinical epigenetics · 2026Article
- miR-135a-5p exerts tumor-suppressive effects in 769P renal carcinoma cells through the TFAP2A/KRT8 signaling axis.In vitro cellular & developmental biology. Animal · 2026Article
- TFAP2A regulates SGPP2 transcription to promote lipid accumulation and activate the Wnt/β-catenin signaling pathway to promote malignant progression in lung adenocarcinoma.Journal of translational medicine · 2026Article
- TFAP2A transcriptionally regulates B3GALT2 to affect gouty arthritis progression through pyroptosis: a study based on machine learning and multi-omics integration analysis.Journal of orthopaedic surgery and research · 2026Article
- Mapping the Subtype-Specific PARP1 ADP-ribosylated Proteome in Breast Cancer Cells.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is the subtype of breast cancer with the highest rates of recurrence and mortality. Transcription factor AP-2 alpha (TFAP2A) plays a key role in modulating the expression of various genes, affecting multiple biological processes such as ferroptosis, and driving the initiation and progression of tumors, including breast cancer. Furthermore, preferentially expressed antigen in melanoma (PRAME), an inhibitor of retinoic acid signaling, was reported to promote TNBC cell migration and invasion. This study aims to explore the effects of TFAP2A and PRAME in TNBC. TFAP2A and PRAME mRNA levels were detected by real-time quantitative polymerase chain reaction (RT-qPCR). TFAP2A, solute carrier family 7 member 11 (SLC7A11), glutathione peroxidase 4 (GPX4), and PRAME protein levels were determined using western blot. Cell invasion, migration, proliferation, and apoptosis were assessed using Transwell, wound healing, colony formation, and flow cytometry. Malondialdehyde (MDA), Fe
Indexed as
Identifiers
40848133What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.